A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.

doi:10.1016/j.ejca.2020.02.048

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.

European journal of cancer (Oxford, England : 1990) - 1 May 2020

Berger Martin D, Ning Yan, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L, Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef

Abstract excerpt

BACKGROUND: Through enhancement of the Wnt signalling pathway, R-spondins are oncogenic drivers in colorectal cancer. Experimental data suggest that the R-spondin/Wnt axis stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis. We therefore hypothesise that variations within R-spondin genes predict outcome in patients with metastatic colorectal cancer (mCRC) treated with upfront FOLFIRI and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Clinical Trials, Phase III as Topic

Share to Fluorouracil

Share to Leucovorin

Share to Patient Selection

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 32305727
DOI: 10.1016/j.ejca.2020.02.048
PMCID: PMC7513926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.PMID 32305727Read ↗

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.Semantic proximity Read ↗

RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunitiesSemantic proximity Read ↗

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.Semantic proximity Read ↗

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.Semantic proximity Read ↗

Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.Semantic proximity Read ↗

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.Semantic proximity Read ↗

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.Semantic proximity Read ↗

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Semantic proximity Read ↗

R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast CancersSemantic proximity Read ↗

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.Semantic proximity Read ↗

R-spondin family biology and emerging linkages to cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.